Lindsay Bealor Greenleaf Discusses Massachusetts’ 1115 Waiver Request with BioPharma Dive
"By rejecting Massachusetts' 1115 waiver request to establish a closed Medicaid formulary and still receive 23.1% mandatory manufacturer rebates, the administration is protecting patients' access to critical treatments and upholding the bargain that Congress struck with states and manufacturers in the 1990s," Greenleaf said in a statement.
[el-text]
Written by David Lim
***excerpt***
“By rejecting Massachusetts’ 1115 waiver request to establish a closed Medicaid formulary and still receive 23.1% mandatory manufacturer rebates, the administration is protecting patients’ access to critical treatments and upholding the bargain that Congress struck with states and manufacturers in the 1990s,” Greenleaf said in a statement.
***end excerpt***
***
[/el-text]
View full article here
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.